Loading stock data…
$4.02-0.03 (-0.74%)
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
ARS Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.02 with a market capitalization of $536M. Wall Street consensus targets $22.50 (4 analysts), implying a +459.7% move over the next 12 months. The stock is currently near its 52-week low of $3.93, remaining 48.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $33.66M↑ | $22.68M↓ | $28.09M↓ | $32.50M↑ | $15.72M |
| Gross Profit | $20.81M↑ | $16.39M↓ | $21.93M↓ | $24.31M↑ | $10.73M |
| Operating Income | -$61.47M↓ | -$60.15M↓ | -$41.47M↑ | -$53.19M↓ | -$47.61M |
| Net Income | -$62.34M↓ | -$60.62M↓ | -$41.32M↑ | -$51.15M↓ | -$44.88M |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal deliv...